PostEra - About the company
PostEra is a series A company based in London (United Kingdom), founded in 2019 by Alpha Lee, Aaron Morris and Matthew Robinson. It operates as an AI based molecular designing software for drug discovery. PostEra has raised $26.2M in funding from Y Combinator and The Clermont. The company has 159 active competitors, including 38 funded and 15 that have exited. Its top competitors include companies like Certara, Astex Pharmaceuticals and Cartography Biosciences.
Company Details
AI-based molecular designing software for drug discovery It uses ML technology for designing molecular compounds to aid in the chemical synthesis of the compounds. It also enables the user to explore chemical space and optimize scaffolds of the lead compound, design the synthetic routes. The company also designs and enables users to order chemical compounds.
- Website
- postera.ai
- Email ID
- *****@postera.ai, *****@postera.ai
Key Metrics
Founded Year
2019
Location
London, United Kingdom
Stage
Series A
Total Funding
$26.2M in 2 rounds
Latest Funding Round
Investors
Ranked
10th among 159 active competitors
Employee Count
41 as on Sep 30, 2026
Similar Companies
Legal entities associated with PostEra
PostEra is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
POSTERA LTD CIN: 12284303 , United Kingdom, Deadpooled | Oct 27, 2019 | - | 3 (As on Oct 31, 2022) |
Sign up to download PostEra's company profile
PostEra's funding and investors
PostEra has raised a total funding of $26.2M over 2 rounds. Its first funding round was on Mar 17, 2020. Its latest funding round was a Series A round on Jan 11, 2022 for $*****. 10 investors participated in its latest round. PostEra has 10 institutional investors and 1 angel investor.
Here is the list of recent funding rounds of PostEra:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 11, 2022 | 1770667 | Series A | 1882724 | 8232246 | 7943316 | 2505046 |
Mar 17, 2020 | 6864762 | Seed | 8503594 | 3448078 | 2665258 |
View details of PostEra's funding rounds and investors
PostEra's founders and board of directors
Founder? Claim ProfileThe founders of PostEra are Alpha Lee, Aaron Morris and Matthew Robinson. Aaron Morris is the CEO of PostEra.
Here are the details of PostEra's key team members:
- Alpha Lee: Co-Founder & CSO of PostEra. Contact Info: 1 email address
- Aaron Morris: Co-Founder & CEO of PostEra. Contact Info: 1 email address
- Matthew Robinson: Co-Founder of PostEra. Contact Info: 1 email address
PostEra's Board of Directors
PostEra's board has 3 active members. Matthew Robinson, Alpha Lee and Aaron Morris are part of team.Here is the list of PostEra's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 6y 11m | |
Team | - | Current | 6y 11m | |
Team | - | Current | 6y 11m |
View details of PostEra's Founder profiles and Board Members
PostEra's employee count trend
PostEra has 41 employees as of Sep 26. Here is PostEra's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
PostEra's Competitors and alternates
Top competitors of PostEra include Certara, Astex Pharmaceuticals and Cartography Biosciences. Here is the list of Top 10 competitors of PostEra, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Certara 2008, Princeton (United States), Public | Provider of a platform for in silico drug discovery and consulting services | - | 65/100 | |
2nd | Astex Pharmaceuticals 1991, Pleasanton (United States), Acquired | Oncology and CNS drug discovery and development using cutting-edge technology | $3M | 64/100 | |
3rd | Cartography Biosciences 2020, Foster City (United States), Series B | Provider of a platform to discover immunotherapeutics | $124M | 63/100 | |
4th | Pharmacelera 2015, Barcelona (Spain), Series A | Hardware and software solutions for computer-aided drug design | $7.1M | 59/100 | |
5th | Oxford Drug Design 2001, Oxford (United Kingdom), Series A | Provider of computer-aided design of antibiotics for MDR infections | $12.4M | 59/100 | |
6th | Inpharmatica 1998, London (United Kingdom), Acquired | Developer of predictive informatics based platform for drug discovery | $75M | 58/100 | |
7th | Genialis 2015, Boston (United States), Series A | Developer of end-to-end bioinformatics software solutions | $16M | 56/100 | |
8th | CytoReason 2016, Haifa (Israel), Series C | Discovering immune system based drugs by biological data analytics | $130M | 55/100 | |
9th | AI-based precision medicine supporting tool for drug discovery | - | 56/100 | ||
10th | PostEra 2019, London (United Kingdom), Series A | AI based molecular designing software for drug discovery | $26.2M | 51/100 |
Looking for more details on PostEra's competitors? Click here to see the top ones
PostEra's Investments and acquisitions
PostEra has made no investments or acquisitions yet.
Reports related to PostEra
Here is the latest report on PostEra's sector:
News related to PostEra
•
•
Pfizer extends AI drug discovery pact with PostEra, adding ADCs to dealEndPoints News•Jan 07, 2025•Pfizer, PostEra
•
PostEra and NIH partner for AI-powered antiviral developmentPharmaceutical Technology•May 19, 2022•PostEra, NIH
•
The tiny Boston startup helping Pfizer with Covid-19 antiviralsThe Business Journals•Jan 18, 2022•PostEra, Pfizer
•
PostEra Secures $24M, Forms $260M AI Lab Collaboration with PfizerHIT Consultant•Jan 11, 2022•Pfizer, PostEra, Breyer Capital, Lifeforce Capital and 5 others
•
PostEra and LifeArc Collaborate on Novel Open Science Initiative to Develop New Antiviral for COVID-19Medical Device News•May 19, 2021•PostEra
•
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug DiscoveryMedianet•Dec 07, 2020•PostEra, Pfizer
•
PostEra and NeuroLucent collaborate to identify small-molecule therapeutics against Alzheimer's diseasePR Newswire•Nov 26, 2020•PostEra, NeuroLucent
•
PostEra and NeuroLucent enter into partnership to identify small-molecule therapeutics for Alzheimer's diseasePR Newswire•Nov 26, 2020•PostEra, NeuroLucent
•
PostEra and NeuroLucent collaborate to identify small molecule therapies for Alzheimer's diseasePR Newswire•Nov 26, 2020•PostEra, NeuroLucent
Are you a Founder ?
FAQs about PostEra
Explore our recently published companies
- Christoph Hein - Lemwerder based, Unfunded company
- Sandra Godwin - Unfunded company
- KCG - Unfunded company
- Omnipresence Exim - Hyderabad based, 2019 founded, Unfunded company
- ValaCare - Toronto based, 2026 founded, Unfunded company
- AI Fairness 360 - Unfunded company
